Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
B
B

Biomerieux


Balita

Biomerieux Receives FDA 510(K) Clearance Of VIDAS TBI

BRIEF-Biomerieux Receives FDA 510(K) Clearance Of VIDAS TBI May 28 (Reuters) - Biomerieux SA BIOX.PA : BIOMERIEUX SA - RECEIVES FDA 510(K) CLEARANCE OF VIDAS TBI (GFAP, UCH-L1) Source text for Workspace: ID:nNDLs53Tm Further company coverage: BIOX.PA (Gdansk Newsroom)
B

Malawi Health Ministry, bioMerieux, Pfizer Form Multisectoral Collaboration On Antimicrobial Resistance

BRIEF-Malawi Health Ministry, bioMerieux, Pfizer Form Multisectoral Collaboration On Antimicrobial Resistance May 23 (Reuters) - Biomerieux SA BIOX.PA : MALAWI MINISTRY OF HEALTH, BIOMÉRIEUX, AND PFIZER FORM COUNTRY'S FIRST MULTISECTORAL COLLABORATION TO HELP ADDRESS ANTIMICROBIAL RESISTANCE Source textL https://tinyurl.com/46ayacaa Further compan
B
P

Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers

BUZZ-Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers ** Barclays initiates the French diagnostics specialist Biomerieux BIOX.PA with "overweight", saying that its organic growth has been "smoother" than the broader in vitro diagnostics peer group ** "The company has managed to grow revenues vs its 2021 base despite COV
B
D

Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight'

BUZZ-Barclays cites DiaSorin's in-line top-line but 'ambitious' margins - starts at 'equal weight' ** Barclays initiates coverage of DiaSorin DIAS.MI with "equal weight", seeing its top-line 9% CAGR revenue estimate for 2024-27 to be in line with the company's mid-term guidance and driven by the launch of new products ** However, the Italian diagno
B
D

Arkema, Fuller Smith & Turner, Siemens Energy

EUROPE RESEARCH ROUNDUP- Arkema, Fuller Smith & Turner, Siemens Energy May 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Fuller Smith & Turner and Siemens Energy, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 117 from EUR 107 * Bytes Technology Group Plc BYIT.L : Deutsche Bank initiates coverage with buy rating * Fuller Smith & Turner Plc FSTA.L : Deutsche Bank initiates coverage with buy
A
A
A
A
B
B
B
B
C
E
E
G
A
A
B
D
G

Dassault Systemes, Husqvarna, Swedbank

EUROPE RESEARCH ROUNDUP-Dassault Systemes, Husqvarna, Swedbank April 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Dassault Systemes, Husqvarna and Swedbank on Friday. HIGHLIGHTS * AstraZeneca AZN.L : Deutsche Bank raises target price to 11000p from 10500p * Dassault Systemes DAST.PA : JP Morgan cuts to neutral from overweight * Husqvarna AB HUSQb.ST : Jefferies raises to buy from hold * London Stock Exchange Group LSEG.L : RB
A
A
A
A
A
A
A
A
A
A
A
B
B
B
B
B
D
D
F
H
I
N
R
S
V
A
A
A
B
B
B
E
F
S

Top of the Street: Galp, Reckitt, Legrand, Biomerieux

BUZZ-Top of the Street: Galp, Reckitt, Legrand, Biomerieux A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Morgan Stanley upgrades Portugal's Galp GALP.LS to "equal-weight" from "underweight", saying its call on Galp has been unsuccessful as the Namibia exploration campaign results have consistently exceeded assumptions ** Jefferies ups Reckitt RKT.L to "hold" from "underperform" as they expect the Enfamil maker to be more supported in H2, when the group
B
L
G

Adriatic Metals, Diageo, GB Group

EUROPE RESEARCH ROUNDUP-Adriatic Metals, Diageo, GB Group April 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adriatic Metals, Diageo and GB Group, on Tuesday. HIGHLIGHTS * Adriatic Metals Plc ADT1.L : Stifel raises target price to 275p from 250p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2400p from 2430p * GB Group Plc GBGP.L : Peel Hunt raises target price to 360p from 340p * H&M HMb.ST : Morgan Stanley raises
A
B
B
D
D
D
G
H
I
L
P
H
G

Bytes Technology, Marks and Spencer, Phoenix

EUROPE RESEARCH ROUNDUP-Bytes Technology, Marks and Spencer, Phoenix April 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bytes Technology, Marks and Spencer and Phoenix, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : RBC raises target price to EUR 250 from EUR 230 * Bytes Technology Group Plc BYIT.L : HSBC raises to buy from hold * Marks and Spencer Group MKS.L : Jefferies raises to buy from hold * Phoenix PHNX.L : Berenberg cut
A
A
A
A
B
B
B
B
E
E
E
E
G
L
L
M
N
P
R
U
A
A
B
B
D
G
I
I
M
R

Alfen, Boliden, Pennon Group

EUROPE RESEARCH ROUNDUP-Alfen, Boliden, Pennon Group April 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfen, Boliden and Pennon Group on Wednesday. HIGHLIGHTS * Alfen ALFEN.AS : Deutsche Bank cuts to hold from buy * Boliden AB BOL.ST : JP Morgan raises to neutral from underweight * Pennon Group Plc PNN.L : RBC raises to outperform rating * Picton Property Income Ltd PCTN.L : Peel Hunt raises to buy from hold * URW URW.PA :
A
A
A
B
B
B
B
B
B
C
C
E
E
E
F
G
H
H
L
N
P
A
A
B
B
B
D

BASF, Cadeler, Edenred

EUROPE RESEARCH ROUNDUP-BASF, Cadeler, Edenred April 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BASF, Cadeler and Edenred, on Wednesday. HIGHLIGHTS * BASF BASFn.DE : Deutsche Bank cuts to hold from buy * Cadeler A/S CADLR.OL : Jefferies raises target price to NOK 70 from NOK 65 * Edenred EDEN.PA : Jefferies initiates coverage with underperform rating; PT EUR 40 * Troax Group AB (Publ) TROAX.ST : Berenberg initiates coverage
A
A
A
B
B
B
E
E
E
G
H
H
I
I
K
L
M
P
R
R
R
S
S
S
S
S
V
W
B
M
S

Slide in defence stocks knocks down Europe's STOXX 600

UPDATE 2-Slide in defence stocks knocks down Europe's STOXX 600 For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window BP gains on higher quarterly upstream energy output forecast Fincantieri shines after Norwegian Cruise Line deal Italy cuts growth forecasts and says debt set to rise Updates with closing prices By Ankika Biswas, Johann M Cherian and Ozan Ergenay April 9 (Reuters) - A sell-off in defence stocks dragged Europe's benchmark stock
A
B
B
L
R
T
A
F
E
F
I
U
G

Biomerieux shares eye best day in 25 mths after better-than-expected Q1

BUZZ-Biomerieux shares eye best day in 25 mths after better-than-expected Q1 ** Shares in Biomerieux BIOX.PA rise 8%, set for best day in 25 months if gains hold, after the company published Q1 organic growth above consensus, and presented new 5-year strategic plan ** The French diagnostics specialist reports Q1 sales of 965.2 million euros ($1.05
B

European shares off to a gloomy start

LIVE MARKETS-European shares off to a gloomy start Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN SHARES OFF TO A GLOOMY START European shares were trading lower on Tuesday, with investors remaining cautious ahead of this week's U.S.
A
B
A
R
E
F
U
G

Biomerieux Aims At Organic Revenue Growth Of +7% 2028

BRIEF-Biomerieux Aims At Organic Revenue Growth Of +7% CAGR 2024-2028 April 9 (Reuters) - Biomerieux SA BIOX.PA : AIMS AT ORGANIC REVENUE GROWTH OF +7%, CAGR2 2024 / 2028 2028 PLAN : DIVIDEND PAY-OUT RATIO POLICY OF AROUND 25% OF THE ANNUAL GROUP NET INCOME GO 28 PLAN: CONTRIBUTIVE OPERATING INCOME BEFORE NON RECURRING ITEMS IMPROVING TO 20% OF SAL
B

Biomerieux Q1 Consolidated Sales Up 6.6% At EUR 965 Million

BRIEF-Biomerieux Q1 Consolidated Sales Up 6.6% At EUR 965 Million April 9 (Reuters) - Biomerieux SA BIOX.PA : CONFIRMS ITS 2024 GUIDANCE FOR SALES AND OPERATING PROFIT, TARGETING AN ORGANIC SALES GROWTH BETWEEN +6% AND +8%, AND A CONTRIBUTIVE OPERATING INCOME BEFORE NONRECURRING ITEMS GROWING AT LEAST BY +10% AT CONSTANT EXCHANGE RATES CONSOLIDATED
B

Berenberg upgrades Biomerieux on growth potential

BUZZ-Berenberg upgrades Biomerieux on growth potential ** Berenberg upgrades Biomerieux BIOX.PA to "buy" from "hold" as it expects new product launches to drive growth for the French diagnostics company ** It points to a "remarkably strong" Q4 performance of Biomerieux's new product in molecular infectious disease diagnostics, SPOTFIRE ** The broke
B

Biomerieux, Pernod Ricard, Remy Cointreau

EUROPE RESEARCH ROUNDUP-Biomerieux, Pernod Ricard, Remy Cointreau March 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Biomerieux, Pernod Ricard and Remy Cointreau, on Thursday. HIGHLIGHTS * Biomerieux SA BIOX.PA : Berenberg raises to buy from hold * Diasorin SpA DIAS.MI : Berenberg cuts to hold from buy * Pernod Ricard PERP.PA : Deutsche Bank raises to hold from sell * Remy Cointreau RCOP.PA : Deutsche Bank raises to buy from
A
A
B
B
C
C
C
C
C
D
E
H
H
I
I
R
R
S
A
A
B
D
P
S



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.